ANGLE presents two posters at EACR
ANGLE plc presented two posters at the EACR Liquid Biopsies Conference in Lyon, France. The first poster demonstrated the effectiveness of combining Parsortix system with Portrait+ CTC staining kit for detecting and characterizing circulating tumor cells (CTCs). In prostate cancer patients, 64% showed CTC positivity, with 67% of positive samples containing CTC clusters. Notably, 77% of CTC-positive patients had only mesenchymal CTCs.
The second poster showcased enhanced multiplexing capabilities in digital PCR for CTC analysis, demonstrating improved molecular characterization potential using QIAGEN's Qiacuity dPCR system with Parsortix-enriched samples. This advancement allows for simultaneous assessment of multiple genes from a single sample.
ANGLE plc ha presentato due poster alla Conferenza sulle Biopsie Liquide EACR a Lione, Francia. Il primo poster ha dimostrato l'efficacia della combinazione del Parsortix system con il kit di colorazione Portrait+ CTC per la rilevazione e caratterizzazione delle cellule tumorali circolanti (CTC). Nei pazienti affetti da cancro alla prostata, il 64% ha mostrato positività per le CTC, con il 67% dei campioni positivi contenenti cluster di CTC. È importante notare che il 77% dei pazienti positivi per CTC presentava solo CTC mesenchimali.
Il secondo poster ha mostrato capacità di multiplexing avanzato nella PCR digitale per l'analisi delle CTC, dimostrando un potenziale migliorato di caratterizzazione molecolare utilizzando il sistema QIAGEN Qiacuity dPCR con campioni arricchiti da Parsortix. Questo progresso consente la valutazione simultanea di più geni da un singolo campione.
ANGLE plc presentó dos carteles en la Conferencia de Biopsias Líquidas de EACR en Lyon, Francia. El primer cartel demostró la efectividad de combinar el sistema Parsortix con el kit de tinción Portrait+ CTC para detectar y caracterizar células tumorales circulantes (CTC). En pacientes con cáncer de próstata, el 64% mostró positividad para CTC, con el 67% de las muestras positivas conteniendo agrupaciones de CTC. Notablemente, el 77% de los pacientes positivos para CTC solo tenían CTCs mesenquimatosos.
El segundo cartel mostró capacidades de multiplexión mejoradas en PCR digital para el análisis de CTC, demostrando un potencial mejorado de caracterización molecular utilizando el sistema QIAGEN Qiacuity dPCR con muestras enriquecidas de Parsortix. Este avance permite la evaluación simultánea de múltiples genes a partir de una sola muestra.
ANGLE plc는 프랑스 리옹에서 열린 EACR 액체 생검 컨퍼런스에서 두 개의 포스터를 발표했습니다. 첫 번째 포스터는 Parsortix 시스템과 Portrait+ CTC 염색 키트를 결합하여 순환 종양 세포(CTC)를 탐지하고 특성화하는 효과를 입증했습니다. 전립선암 환자 중 64%가 CTC 양성 판정을 받았으며, 양성 샘플의 67%에는 CTC 클러스터가 포함되어 있었습니다. 특히 CTC 양성 환자의 77%는 오직 간엽 CTC만 가지고 있었습니다.
두 번째 포스터는 CTC 분석을 위한 디지털 PCR에서 향상된 다중화 기능을 선보이며, Parsortix으로 농축된 샘플을 이용해 QIAGEN의 Qiacuity dPCR 시스템을 사용하여 분자 특성화의 가능성을 높였습니다. 이 발전은 단일 샘플에서 여러 유전자를 동시에 평가할 수 있도록 합니다.
ANGLE plc a présenté deux affiches lors de la Conférence sur les Biopsies Liquides EACR à Lyon, France. La première affiche a démontré l'efficacité de la combinaison du système Parsortix avec le kit de coloration Portrait+ CTC pour détecter et caractériser les cellules tumorales circulantes (CTC). Parmi les patients atteints de cancer de la prostate, 64 % ont montré une positivité pour les CTC, avec 67 % des échantillons positifs contenant des clusters de CTC. Notamment, 77 % des patients positifs pour les CTC n'avaient que des CTC mésenchymateux.
La deuxième affiche a mis en avant des capacités de multiplexage améliorées dans la PCR numérique pour l'analyse des CTC, démontrant un potentiel de caractérisation moléculaire amélioré en utilisant le système QIAGEN Qiacuity dPCR avec des échantillons enrichis par Parsortix. Cette avancée permet l’évaluation simultanée de plusieurs gènes à partir d’un échantillon unique.
ANGLE plc präsentierte zwei Poster auf der EACR-Konferenz zu Flüssigbiopsien in Lyon, Frankreich. Das erste Poster zeigte die Wirksamkeit der Kombination des Parsortix-Systems mit dem Portrait+ CTC-Färbesatz zur Erkennung und Charakterisierung von zirkulierenden Tumorzellen (CTCs). Bei Prostatakrebspatienten wiesen 64% eine CTC-Positivität auf, wobei 67% der positiven Proben CTC-Cluster enthielten. Bemerkenswert ist, dass 77% der CTC-positiven Patienten nur mesenchymale CTCs hatten.
Das zweite Poster zeigte verbesserte Multiplexing-Fähigkeiten in der digitalen PCR zur CTC-Analyse und demonstrierte das verbesserte Potenzial zur molekularen Charakterisierung mit dem Qiagen Qiacuity dPCR-System unter Verwendung von mit Parsortix angereicherten Proben. Dieser Fortschritt ermöglicht die gleichzeitige Bewertung mehrerer Gene aus einer einzigen Probe.
- 64% detection rate of CTCs in prostate cancer patients using Parsortix system
- Successful demonstration of enhanced multiplexing capabilities for molecular characterization
- Technology proves effective in detecting both epithelial and mesenchymal CTCs
- None.
PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCE
Two posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation of CTCs
GUILDFORD, SURREY / ACCESSWIRE / November 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce its participation at the European Association for Cancer Research (EACR) Liquid Biopsies Conference being held in Lyon, France from 12 to 14 November 2024.
ANGLE presented two posters at the EACR Liquid Biopsies Conference:
1. Combined epitope-independent microfluidic isolation and advanced staining of circulating tumour cells isolated from metastatic prostate cancer blood samples
This poster presentation reports on the utility of combining ANGLE's Parsortix® system for CTC capture with the Portrait®+ CTC staining kit for CTC detection and phenotypic characterisation. This workflow provides an efficient, standardised solution for the characterisation of multiple CTC phenotypes (epithelial, mesenchymal and those transitioning).
In a cohort of prostate cancer patients
This study also demonstrates the potential utility of this workflow for longitudinal patient monitoring, where changes in CTC number (including their absence) and phenotype are associated with patient status. The study presented two case studies of metastatic prostate cancer patients with CTC results preceding a change in patient clinical status over time.
2. Enhancing Multiplexing Capabilities in Digital PCR for Circulating Tumour Cell Analysis Using Amplitude-Based methodology
Molecular characterisation of CTCs is particularly important in the metastatic disease setting, where tissue biopsies may not be possible or repeatable, and there is a need for real-time tumour analysis and longitudinal monitoring of disease progression and treatment response. Recent advances in digital PCR (dPCR) technology, combined with multiplexing capabilities, have enhanced the ability to perform precise molecular characterisation from even a small number of CTCs.
This proof-of-concept study demonstrates that using amplitude-based multiplexing with QIAGEN's Qiacuity dPCR system can increase the number of genes that can be assessed simultaneously in a Parsortix-enriched CTC sample. This method of molecular characterisation improves the ability to report a wider range of genetic markers from a single sample with the potential to provide a more comprehensive view into tumour biology.
Chief Scientific Officer, Karen Miller, commented:
"We are pleased to have presented two posters at the EACR Liquid Biopsies Conference. The results of these studies further demonstrate the utility of ANGLE's technology for capturing and characterising CTCs at both the cellular and molecular level. Advances in molecular characterisation will be key to building a comprehensive picture of cancer and providing insight during targeted drug discovery and development. We are continuing to develop Parsortix-based molecular assays to provide a range of highly sensitive and specific assays to serve the needs of our pharma customers."
The posters are available for review at: https://angleplc.com/resources/posters/
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Berenberg (NOMAD and Broker) | +44 (0) 20 3207 7800 |
FTI Consulting |
|
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
All results reported in this announcement and any other products and services are for research use only and not for use in diagnostic procedures.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on accesswire.com
FAQ
What were the key findings of ANGLE's Parsortix system in prostate cancer patients?
What new technology did ANGLE (ANPCY) showcase at the EACR 2024 conference?
How does ANGLE's Parsortix system improve CTC detection in cancer patients?
